Immuron Ltd — Regulatory Filings 2007

Apr 25, 2007

Company Announcement

Appointment of CEO

Thursday 26 April 2007

The Board is pleased to announce the appointment of Dr Zeil Rosenberg as the new Chief Executive Officer of Anadis Ltd (ASX:ANX). Dr Rosenberg will be based in the New York area and will manage the transformation of Anadis towards programs targeted at high value markets. Dr Rosenberg has been working with Anadis during the past several months through the consulting firm BioVance Medical LLC, of which he is a principal.

Dr. Rosenberg is a recognized physician-leader and business executive with over 20 years of achievement in the global healthcare industry, with experience including 8 years at Becton Dickinson & Co. as Worldwide Business Leader and Medical Director for Immunization. Dr. Rosenberg serves as Chairperson, Committee on Terrorism and Emergency Preparedness at the American College of Preventive Medicine and is on the faculty of Columbia University's Mailman School of Public Health.

This appointment has been initiated by the Board in order to bring greater focus to the emerging opportunities for Anadis and its technologies, particularly in the increasingly important areas of influenza, bio-defence programs, nosocomial disease (hospital acquired infections) and gastrointestinal disease such as inflammatory bowel disease (IBD). Directors believe these programs will generate significant shareholder value when developed in the appropriate markets and receive strong global endorsement, through initiatives including international research collaborations and clinical programs.

Dr Rosenberg's initial focus will be on reviewing the vision and strategy of the business and coordinating and improving our existing commercialisation strategies and repositioning our research programs through international government, research and commercial collaborations.

For further information, please contact:

Arie Nudel - Investor Relations Email: arie.n@anadis.com.au Tel: +61 3 9358 6388

Roman Zwolenski – Executive Director Email: roman.z@anadis.com.au Tel: +61 3 9358 6388

About Anadis Limited:

Anadis is a biotechnology company headquartered in Melbourne. Victoria and listed on the Australian Stock Exchange listed (ASX Symbol: ANX). The Company is strongly research-based and specialises in developing fast-acting "passive" immunity solutions to a range of diseases caused by bacteria and viruses. Naturally-derived polyclonal antibodies and bioactives produced on a large scale through hyperimmunised dairy cattle are a key element of the Company's extensive and proprietary technology and products.

Products include:

• $\bullet$ Travelan, which significantly decreases the risk of the medical condition known as travellers' diarrhoea and the symptoms of gastrointestinal disorders caused by bacterially-contaminated food and water. Travelan has been launched and is available in several countries
• EVProtec a preventative product containing antibodies against Enterovirus 71, a virus which $\bullet$ causes epidemics of a debilitating polio-like illness, as well as hand, foot and mouth disease, in Southeast Asia. The product is in the pre-launch stage.

Research programs include:

• $\bullet$ The "Ectoplasm" Program A project in conjunction with Australian emergency response agencies developing a system for the containment and decontamination of hazardous materials.
• A set of Biodefence and Respiratory Protection technologies, focused on short-term immediate protection from airborne infections such as anthrax and plague.
• The Influenza Program utilising antibodies and their fragments as inhalants for the prevention and treatment of influenza, including avian flu.
• Bio-Shield 10 a range of "bio-shielding" technologies which shield orally administered proteins $\bullet$ from degradation during passage through the stomach. Initially targeted for use in the probiotic market, Bio-Shield 10 is the basis of a novel oral and respiratory tract delivery system being developed for the next generation of vaccines and therapeutic proteins.

ANADIS - Antibodies against Disease

Visit our websites: www.anadis.com.au and www.travelan.com